ClinicalTrials.gg
TerminatedNCT02325492Updated Oct 5, 2015

Medical Dissolution of Cholesterol Gallstones Using Oral Aramchol - A Proof of Concept Phase IIa Study

A Phase 2 interventional study of Aramchol and Placebo in Gallstones, sponsored by Galmed Pharmaceuticals Ltd. Terminated at 1 site in Israel. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-10-05.

Sponsored by Galmed Pharmaceuticals Ltd · Phase 2, Interventional, and Treatment

Why this study was terminated
Protocol redesign

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a one center, Phase IIa, randomized, double blind, placebo controlled study designed to evaluate the efficacy and safety of two Aramchol doses in subjects 18 to 75 years of age, with newly formed cholesterol gallstones in their gallbladder following bariatric surgery confirmed by gallbladder ultrasound ..

Read the detailed description

This is a one center, Phase IIa, randomized, double blind, placebo controlled study designed to evaluate the efficacy and safety of two Aramchol doses in subjects 18 to 75 years of age, with newly formed cholesterol gallstones in their gallbladder following bariatric surgery confirmed by gallbladder ultrasound performed in a period of 3 \& 6 months following surgery before entering the study. All patients have ultrasonography evidence of clear gallbladder before the bariatric surgery.

Eligible subjects will be enrolled into three treatments arms: Aramchol 400 mg and 600 mg tablets and placebo tablets in ratio 1:1:1.

The subjects will be evaluated at study sites for 6 scheduled visits: at weeks -4 - 0 screening visit, Day 0 - baseline, weeks 2, 4, 8\& 12 (Termination/early termination visit).

During the screening period the presence and number of cholesterol gallstones will be evaluated by gallbladder Ultrasound.

During the study the following assessments will be performed:

  • Vital signs will be measured at each study visit.
  • A physical examination will be performed at the screening visit, and termination/early termination visit.
  • The following safety blood tests will be performed: complete blood count (CBC), serum chemistry (including electrolytes, liver enzymes, direct and total bilirubin, glucose, HbA1C, lipid profile which include cholesterol, HDL, LDL and VLDL, CPK, creatinine, urea, albumin, alkaline phosphatase), coagulation (fibrinogen, PT/INR, aPTT), ESR and urinalysis during the screening visit, baseline, week 2, 4, 8 and 12 (termination/early termination) visits. Serology (HBV, HCV and HIV) will be performed during the screening visit. β-hCG in women of child bearing potential will be performed during the screening visit.
  • Body weight will be measured in screening, baseline and end of treatment visits. Height will be measured during the screening visit.
  • ECG will be performed during the screening and end of treatment visits.
  • Blood for Metabolomics will be collected at baseline and end of treatment visits.
  • Ultrasound will be performed at screening visit, baseline, week 4, 8 and termination/early termination visits.
  • Adverse events will be monitored throughout the study.
  • Concomitant Medications will be monitored throughout the study.
02

Conditions studied

  • Gallstones

Browse trials for

Keywords

  • bariatric surgery
  • NASH
  • ARAMCHOL
03

In context

Gallstones

200 studies on the registry are indexed under Gallstones; 36 are open to participants now.

This study's enrollment of 10 is below the median of 98 across 121 interventional studies indexed under Gallstones.

Browse Gallstones studies →

Lead sponsor

Galmed Pharmaceuticals Ltd is the lead sponsor of 10 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female age 18 to 75 years.
  2. Presence of newly formed gallstones (size up to 6 mm) with or without sludge diagnosed by ultrasound within 3 or 6 months after bariatric surgery following normal ultrasound.
  3. Bariatric surgery conducted during the last 12 months
  4. Patients with "sleeve gastrectomy" or laparoscopic banding of the upper stomach will be included.
  5. Signature of the written .
  6. Negative pregnancy test at study entry for females of child bearing potential.
  7. Females of child bearing potential practicing reliable throughout the study period (not including oral contraceptives).
  8. Hypertensive patients must be well controlled by stable dose of anti-hypertensive medication for at least 2 months prior to screening (and the stable dose can be maintained throughout the study).
  9. Patients treated with vitamin E(>400IU/die), or Polyunsaturated fatty acid (>2g/d) or Ursodeoxycholic acid or fish oil can be included if drugs are stopped at least 3 months prior to study enrollment to the study and up to it end.
  10. For patients with type 2 Diabetes, glycaemia must be controlled (Glycosylated ≤ 8% while any HbA1C increment should not exceed 1% during 6 month prior to enrollment). If glycaemia is controlled by medications, qualitative change is not permitted within 3 months prior to randomization and should be avoided during the study. Treatments with Metformin, Sulfamides and Insulin are authorized. Sulfamides and insulin are permitted if glycaemia is self-monitored by the patient.

Exclusion criteria

Exclusion Criteria:

  1. Patients with ultrasonography evidence of gallstones in gallbladder before having the bariatric surgery.
  2. Patients with no clear ultrasonography evidence of gallstones -free gallbladder during the year prior their bariatric surgery.
  3. Patients with ultrasonography evidence of gallstones more than 1 year following bariatric surgery.
  4. Patients with ultrasonography evidence of gallstones in size greater than 9 mm less than 1 year following bariatric surgery.
  5. Weight >140 Kg or >40
  6. Known alcohol and/or any other drug abuse or dependence in the last five years
  7. Known history or presence of cardiovascular, hepatic, gastrointestinal, neurologic, pulmonary, endocrine, psychiatric, neoplastic disorder or nephritic syndrome.
  8. History or presence of any disease or condition known to interfere with the absorption, distribution, metabolism or excretion of drugs including bile salt metabolism (e.g. inflammatory bowel disease (IDB); previous intestinal (ileal or colonic) operation; chronic pancreatic; celiac disease or previous vagotomy
  9. Uncontrolled blood pressure
  10. Patients with
  11. Patients with renal dysfunction \< 60.
  12. Patients with pancreatitis, cholangitis or cholecystitis in the previous 4 months.
  13. Women who are pregnant or breastfeeding
  14. Type 1 Diabetes.
  15. .Metformin, Fibrates, Statins, Insulin, Sulfonilurea not provided on a stable dose in the last 6 months.
  16. Patients who are treated with Valproic acid, Tamoxifen, Methotreksate, Amiodaron.
  17. Treatment with Rifaximin.
  18. Homeopathic and/or Alternative treatments. Any treatment should be stopped before the screening period.
  19. Serum creatine phosphokinase (CPK), , AST and/or alkaline phosphatase >3X the (ULN). Patients with an intermittent CPK elevation may have the repeated measurement prior to randomization; a CPK retest > 3X ULN leads to exclusion.

    -

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Aramchol 400 mg

    • One tablet of Aramchol 400 mg and one tablet of Placebo

    Drug: Aramchol · Drug: Placebo · Device: Ultrasound

  • Experimental
    Aramchol 600 mg

    • One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.

    Drug: Aramchol · Device: Ultrasound

  • Placebo comparator
    Placebo

    • Two tablet of Aramchol matching placebo.

    Drug: Placebo · Device: Ultrasound

Interventions

06

What researchers measure

Primary outcomes

  1. Complete dissolution of existing gallstones proven by repeated US examined gallbladder

    Change from baseline measured by US scan

    Time frame: At baseline and week 12

Secondary outcomes

  1. Decrease of more than a 50% in number of stones. (change from baseline)

    change from baseline measured by US scan

    Time frame: At baseline and week 12

  2. Prevention of formation of new gallstones during the study period

    change from baseline measured by US scan

    Time frame: At baseline and week 12

  3. Dissolution of sludge.

    change from baseline measured by US scan

    Time frame: At baseline and week 12

07

Study locations

1 site
  • Assuta Medical Center
    Tel Aviv, Israel
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2014
First posted
Dec 25, 2014
Start
Oct 2014
Primary completionActual
Oct 2015
CompletionActual
Oct 2015
Last update
Oct 5, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02325492
Lead sponsor
Galmed Pharmaceuticals Ltd
Responsible party
Sponsor
First posted
Dec 25, 2014
Start date
Oct 2014
Primary completion
Oct 2015
Completion
Oct 2015
Last update
Oct 5, 2015

Study contacts

Asnat Raziel, MD
principal investigator · Assuta Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aramchol

Start the discussion